COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Behnood Bikdeli, MD, MS, Mahesh V. Madhavan, MD, David Jimenez, MD, PhD, Taylor Chuich, PharmD, Isaac Dreyfus, MD, Elissa Driggin, MD, Caroline Der Nigoghosian, PharmD, Walter Ageno, MD, Mohammad Madjid, MD, MS, Yutao Guo, MD, PhD, Liang V. Tang, MD, Yu Hu, MD, Jay Giri, MD, MPH, Mary Cushman, MD, MSc, Isabelle Quéré, MD, PhD, Evangelos P. Dimakakos, MD, C. Michael Gibson, MD, Giuseppe Lippi, MD, Emmanuel J. Favaloro, PhD, Jawed Fareed, PhD, Joseph A. Caprini, MD, MS, Alfonso J. Tafur, MD, MS, John R. Burton, BS, Dominic P. Francesese, MPH, Elizabeth Y. Wang, MD, Anna Falanga, MD, Claire McLintock, MD, Beverley J. Hunt, MD, Alex C. Spyropoulos, MD, Geoffrey D. Barnes, MD, MSc, John W. Eikelboom, MBBS, Ido Weinberg, MD, Sam Schulman, MD, PhD, Marc Carrier, MD, MSc, Gregory Piazza, MD, MS, Joshua A. Beckman, MD, P. Gabriel Steg, MD, Greg W. Stone, MD, Stephan Rosenkranz, MD, Samuel Z. Goldhaber, MD, Sahil A. Parikh, MD, Manuel Monreal, MD, PhD, Harlan M. Krumholz, MD, SM, Stavros V. Konstantinides, MD, PhD, Jeffrey I. Weitz, MD, Gregory Y.H. Lip, MD

PII: S0735-1097(20)35008-7
DOI: https://doi.org/10.1016/j.jacc.2020.04.031
Reference: JAC 27284

To appear in: Journal of the American College of Cardiology

Received Date: 15 April 2020
Accepted Date: 15 April 2020

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Running Head: COVID-19 and Thrombotic Disease

Behnood Bikdeli, MD, MS1,2,3, Mahesh V. Madhavan, MD1,3,4, David Jimenez MD, PhD4, Taylor Chuich, PharmD1, Isaac Dreyfus, MD1, Elissa Driggin, MD1, Caroline Der Nigoghossian, PharmD1, Walter Ageno, MD5, Mohammad Madjid, MD, MS6, Yutao Guo, MD, PhD7, Liang V. Tang, MD8, Yu Hu, MD8, Jay Giri, MD, MPH9,10,11, Mary Cushman, MD, MSc12, Isabelle Quéré, MD, PhD13, Evangelos P. Dimakakos, MD14, C. Michael Gibson, MD15,16, Giuseppe Lippi, MD17, Emmanuel J. Favaloro, PhD18,19, Jawed Fareed, PhD20, Joseph A. Caprinid, MD, MS21, Alfonso J. Tafur, MD, MS21,22, John R. Burton, BS1, Dominic P. Francese, MPH3, Elizabeth Y. Wang, MD1, Anna Falanga, MD13, Claire McIntock, MD24, Beverley J. Hunt, MD25, Alex C. Spyropoulos, MD26, Geoffrey D. Barnes, MD, MSc27,28, John W. Eikelboom, MBBS29, Idol Weinberg, MD30, Sam Schulman, MD, PhD31,32,34, Marc Carrier, MD, MSc32, Gregory Piazza, MD, MS35,36,37, Joshua A. Beckman, MD34, P. Gabriel Steg, MD35,36,37, Gregg W. Stone, MD38, Stephan Rosenkranz, MD39, Samuel Z. Goldhaber, MD40, Sahil A. Parikh, MD1,3, Manuel Monreal, MD, PhD40, Harlan M. Krumholz, MD, SM2,41, Stavros V. Konstantinides, MD, PhD42, Jeffrey I. Weitz, MD43,44, Gregory Y.H. Lip, MD45,46

Endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the North American Thrombosis Forum (NATF), the European Society of Vascular Medicine (ESVM), and the International Union of Angiology (IUA). Supported by the ESC Working Group on the Pulmonary Circulation and Right Ventricular Function (SR, SK).

From 1NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; 2Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; 3Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; 4Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (IRYCS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; 5Department of Medicine and Surgery, University of Insubria, Varese, Italy; 6McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas; 7Department of Cardiology, Chinese PLA General Hospital, Beijing, China; 8Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 9Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia; 10Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia; 11Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; 12The University of Vermont Medical Center, Burlington, Vermont; 13Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN network, Montpellier, France; 14Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece; 15Harvard Medical School, Boston, Massachusetts; 16Beth Israel Deaconess Medical Center, Boston, Massachusetts; 17Laboratory of Clinical Chemistry and Haematology, University Hospital of Verona, Verona, Italy; 18Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia; 19Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia;
Loyola University Medical Center, Chicago, Illinois; 21 Pritzker School of Medicine at the University of Chicago, Chicago, Illinois; 22 Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois; 23 University of Milan Bicocca, Monza, Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 24 Auckland City Hospital, Auckland, New Zealand; 25 St Thomas’ Hospital, London, United Kingdom; 26 The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York; 27 Center for Bioethics and Social Science in Medicine, 28 Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan; 29 Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; 30 Massachusetts General Hospital, Boston, Massachusetts; 31 Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 32 The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 33 Brigham and Women’s Hospital, Boston, Massachusetts; 34 Vanderbilt University School of Medicine, Nashville, Tennessee; 35 FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM U1148, Paris, France; 36 Université Paris, Paris, France; 37 Imperial College, Royal Brompton Hospital, London, United Kingdom; 38 The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; 39 Department of Cardiology, Heart Center at the University of Cologne, and Cologne Cardiovascular Research Center (CCRC), University of Cologne, Germany; 40 Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Universidad Católica de Murcia, Barcelona, Spain; 41 Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut; 42 Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany; 43 McMaster University, Hamilton, Ontario, Canada; 44 Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada; 45 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; 46 Aalborg University, Aalborg, Denmark

*Drs. Bikdeli and Madhavan contributed equally to this manuscript.

Disclosures

Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of IVC filters.

Dr. Madhavan reports being supported by an institutional grant by the National Institutes of Health/ National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854).

Dr. Jimenez has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI and Sanofi; served as a speaker or a member of a speakers’ bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, ROVI and Sanofi; received grants for clinical research from Daiichi Sankyo, Sanofi and ROVI. Dr. Hu has nothing to disclose.

Dr. Chuich has nothing to disclose.

Dr. Dreyfus has nothing to disclose.

Dr. Driggin has nothing to disclose.

Dr. Der Nigoghossian has nothing to disclose.
Dr. Tang has nothing to disclose.

Dr. Ageno has received honoraria from Boehringer Ingelheim, Bayer Pharmaceuticals, BMS-Pfizer, Daiichi-Sankyo, Aspen, Sanofi, Portola, Janssen. Research support from Bayer Pharmaceuticals.

Dr. Dimakakos receives consulting fees from Sanofi and Leo.

Dr. Lippi has nothing to disclose.

Dr. Favaloro has nothing to disclose.

Dr. Fareed has nothing to disclose.

Dr. Caprini: Steering committee – Janssen R&D; bleeding advisory board – Pfizer; honorarium – Sanofi; consultant – Recovery Force; advisory board – Bristol-Myers Squibb, Alexion Pharmaceuticals.

Dr. Cushman has nothing to disclose.

Dr. Barnes reports consulting for Pfizer/Bristol-Myers Squib, Janssen, Portola, and AMAG Pharmaceuticals. Grant funding from Pfizer/Bristol-Myers Squibb and Blue Cross Blue Shield of Michigan.

Dr. Cushman has nothing to disclose.

Dr. Giri is on the Advisory Boards for Astra Zeneca, Philips Medical, and Inari Medical, receives Research Grants to Institution from Recor Medical and St Jude Medical, and receives Personal Fees for Trial Adjudication from New England Research Institute.

Dr Quéré has received honoraria from Bayer Pharmaceuticals, BMS-Pfizer, Leo Pharma and Aspen.

Dr. Falanga reports being a speaker at corporate symposia for Bayer, Pfizer, and Sanofi.

Dr Spyropoulos reports receiving consulting fees from Boehringer Ingelheim, BMS, Janssen, Bayer, Portola, and the ATLAS Group, and research funding from Boehringer Ingelheim, and Janssen.

Dr. Carrier reports Research funding from BMS, LEO Pharma and Pfizer and consultancy honoraria from BMS, Bayer, Pfizer, LEO Pharma, Servier and Sanofi.

Dr. McLintock has nothing to disclose.

Dr. Hunt reports she takes no monies in any form from pharmaceutical companies producing thrombotic drugs. She is chair of the steering group of World Thrombosis Day and Medical Director of Thrombosis UK; two non-for-profit organisations from which she takes no fees.

Dr. Weinberg reports consulting fees for Magneto thrombectomy solutions.

Dr. Piazza has received significant research grant support from BTG International, Bristol Myers Squibb, Daiichi-Sankyo, Bayer, Portola, and Janssen and modest consulting fees from Pfizer and Thrombolex.

Dr. Schulman reports research grants from Octapharma and Boehringer-Ingeleim and honoraria from Alnylam, Bayer, Boehringer-Ingeleim, Bristol-Myers Squibb, Daiichi-Sankyo and Sanofi.

Dr. Beckman is on the Advisory Boards for Amgen, Astra Zeneca, Glaxo Smith Kline, and Janssen, on the DSMB for Bayer, and Novartis, receives consulting fees from JanOne, and personal fees for Trial Adjudication from Sanofi.

Dr. Rosenkranz: reports remunerations for consultancy and/or lectures from Abbott, Acceleron, Actelion, AstraZeneca, Bayer, BMS, Janssen, MSD, Novartis, Pfizer, United Therapeutics. Research grants to institution from Actelion, AstraZeneca, Bayer, Novartis; Deutsche Forschungsgemeinschaft (DFG), Else-Bundesministerium für Bildung und Forschung (BMBF), Kröner-Fresenius-Stiftung (EKFS).
Dr. Steg reports receiving research grants from Amarin, Bayer, Sanofi, and Servier, and is in the Steering Committee, DSMB or CEC for clinical trials for: Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, Servier, and receives speaker or consultant fees from: Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, and Servier.

Dr. Stone has received speaker or other honoraria from Cook, Terumo, QOOL Therapeutics and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, Valfix.

Dr. Parikh reports institutional grants/research support from Abbott Vascular, Shockwave Medical, TriReme Medical, Surmodics, and Silk Road Medical; consulting fees from Terumo and Abiomed; and Advisory Board participation for Abbott, Boston Scientific, CSI, Janssen, Medtronic and Philips.

Dr. Monreal reports that he served as an advisor or consultant for Sanofi, Leo Pharma and Daiichi Sankyo. Also, he received a nonrestricted educational grant by Sanofi and Bayer to sponsor the RIETE registry.

Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company.

Dr. Konstantinides reports research grants from Bayer AG, Boehringer Ingelheim, Actelion - Janssen; educational grants from Biocompatibles Group UK - Boston Scientific, Daiichi Sankyo; lecture fees from Bayer AG, Pfizer-Bristol-Myers Squibb, MSD, all outside the submitted work.

Dr. Weitz serves as a consultant and received honoraria from Bayer, Janssen, JnJ, BMS, Pfizer, Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Merck, Servier, Anthos, Ionis, and PhaseBio.

Dr. Lip reports that he is a Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

**Corresponding Authors:**

Behnood Bikdeli, MD, MS

New York-Presbyterian Hospital/ Columbia University Irving Medical Center
622 West 168th St, PH 3-347, New York, NY 10032
Phone/ Fax: 212-305-6354
Email: bb2813@cumc.columbia.edu, Behnood.bikdeli@yale.edu
Twitter handle: @bbikdeli

Mahesh Vasantha Madhavan, MD
New York-Presbyterian Hospital/ Columbia University Irving Medical Center
622 West 168th St, PH 3-347, New York, NY 10032
Phone/ Fax: 212-305-6354
Email: mvm2122@cumc.columbia.edu
Twitter handle: @MVMadhavanMD

Acknowledgments
The authors would like to thank Kathryn Mikkelsen, MBA, from the North American Thrombosis Forum, and Adriana Visonà, MD, from the European Society of Vascular Medicine for their comments related to this initiative. The authors would like to credit Julie Der Nigoghossian for assistance with graphic design.
ABSTRACT
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

KEYWORDS: Coronavirus disease 2019, SARS-CoV-2, thrombosis, antithrombotic therapy, anticoagulant, antiplatelet

ABBREVIATIONS
ACS = acute coronary syndromes
COVID-19 = coronavirus disease 2019
DAPT = dual antiplatelet therapy
DIC = disseminated intravascular coagulation
DOAC = direct oral anticoagulant
DVT = deep vein thrombosis
ECMO = extracorporeal membrane oxygenation
LMWH = low-molecular-weight heparin
PE = pulmonary embolism
PERTs = pulmonary embolism response teams
SARS-CoV2 = severe acute respiratory syndrome coronavirus 2
STEMI = ST-segment elevation myocardial infarction
UFH = unfractionated heparin
VEGF = vascular endothelial growth factor
VKA = vitamin-K antagonist
VTE = venous thromboembolism
Introduction

The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), now deemed a pandemic by the World Health Organization (1-3). COVID-19 has a number of important cardiovascular implications (4-6). Patients with prior cardiovascular disease are at higher risk for adverse events from COVID-19. Individuals without a history of cardiovascular disease are at risk for incident cardiovascular complications (5).

There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease (hereafter collectively referred to as thrombotic disease for brevity). First, the direct effects of COVID-19 or the indirect effects of infection, such as through severe illness and hypoxia, may predispose patients to thrombotic events. Preliminary reports suggest that hemostatic abnormalities, including disseminated intravascular coagulation (DIC), occur in patients affected by COVID-19 (7,8). Additionally, the severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks (Table 1) (9,10). Second, investigational therapies for treating COVID-19 may have adverse drug-drug interactions with antiplatelet agents and anticoagulants. Third, the pandemic, because of resource allocations or social distancing recommendations, may adversely affect the care of patients without COVID-19 but who present with thrombotic events. For example, (mis)perception that antithrombotic agents confer increased risk for contracting COVID-19, may lead to untoward interruption of anticoagulation by some patients.

The current manuscript, authored by an international collaborative of clinicians and investigators, summarizes the pathogenesis, epidemiology, treatment, and available outcome data
related to thrombotic disease in patients with COVID-19, as well as management of thrombotic events in patients without COVID-19 during this pandemic. Although the focus is on the prevention and management of venous thromboembolism (VTE) and antithrombotic therapy for acute coronary syndromes (ACS), many of the recommendations are relevant to other conditions requiring antithrombotic therapy. We provide clinical guidance, when feasible, and also identify areas that require urgent attention for future research.

**Methodological Considerations**

Every effort was made to provide a comprehensive assessment of the published evidence (MEDLINE with PubMed interface, date of last search: April 12, 2020). To accommodate the rapidly-evolving nature of information and concern for the delay between completion of studies and their publication, we also reviewed manuscripts on two pre-print servers (https://www.medrxiv.org/ and https://www.ssrn.com/index.cfm/en/coronavirus/, date of last search April 12, 2020). We acknowledge that the manuscripts from the latter two sources are not peer-reviewed.

There is international variability in preventive measures and testing strategies by local authorities, diagnostic tests availability, access to care and treatment strategies, as well as variability in outcome reporting for COVID-19. These issues influence the reported diagnosed cases, casualties, and in turn case-fatality rates. Moreover, to date, we lack large prospective cohorts. The existing evidence, including data on thrombotic complications, is derived primarily from small and retrospective analyses (Figure 1).

The current document represents an effort to provide general guidance for patient-care related to thrombosis and antithrombotic therapy. Given the limitations of the evidence base, the steering committee (BB, MVM, JIW, SK, SZG, AT, MM, HMK, GYHL) chose several
questions that seemed more challenging but relevant to patient care (11). These questions were sent to the entire group of authors twice. The Delphi method was implemented to provide consensus-based guidance. The questions included considerations for prophylactic or therapeutic anticoagulant regimens among various subgroups of patients with COVID-19, and antithrombotic therapy in the setting of suspected or confirmed DIC.

Pathogenesis and Transmission

SARS-CoV2 is a single-strand RNA coronavirus, which enters human cells mainly by binding the angiotensin converting enzyme 2 (ACE2) (12), which is highly expressed in lung alveolar cells, cardiac myocytes, the vascular endothelium, and other cells (1,13). SARS-CoV2 is transmitted primarily after viral particles are inhaled and enter the respiratory tract (1). In addition, the virus can survive for 24-72 hours on surfaces, depending on the type of surface, which enables fomite transmission (14).

Initial symptoms of COVID-19 overlap with other viral syndromes, and include fever, fatigue, headache, cough, shortness of breath, diarrhea, headaches, and myalgias (15-17). As with other virulent zoonotic coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has the potential to result in severe illness including systemic inflammatory response syndrome, acute respiratory disease syndrome (ARDS), multi-organ involvement, and shock (18). Although older age and comorbidities such as cardiovascular disease confer a higher risk for severe disease, young and otherwise healthy patients are also at risk for complications (19).

Common laboratory abnormalities found in patients with COVID-19 include lymphopenia (15) and elevation in lactate dehydrogenase and inflammatory markers such as, C-
reactive protein, D-dimer, ferritin and interleukin-6 (IL-6) (20). IL-6 levels may correlate with
disease severity, and a procoagulant profile (21).

**COVID-19 and Hemostasis Parameters**

The most consistent hemostatic abnormalities with COVID-19 include mild
thrombocytopenia (22) and increased D-dimer levels (23), which are associated with a higher
risk of requiring mechanical ventilation, intensive care unit [ICU] admission, or death. Data
related to other tests are less certain and often contradictory (24,25). Disease severity is variably
associated with prolongation of the prothrombin time (PT) and international normalized ratio
(INR) (1,20,26), and thrombin time (TT) (27), and variably by a trend toward shortened activated
partial thromboplastin time (aPTT) (1,16,19,28). Recently, Tang et al. (7) assessed 183 patients
with COVID-19, 21 of whom (11.5%) died. Among the notable differences between patients
who died and those who survived were increased levels of D-dimer and fibrin degradation
products ([FDPs], ~3.5- and ~1.9-fold increase, respectively) and PT prolongation (by 14%,
P<0.001). Further, 71% of COVID-19 patients who died fulfilled the International Society on
Thrombosis and Haemostasis (ISTH) criteria (29) for DIC, compared with only 0.6% among
survivors. Collectively, these hemostatic changes indicate some forms of coagulopathy that may
predispose to thrombotic events (**Central Illustration**), although the cause is uncertain.

Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of
SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic
inflammatory response syndrome (SIRS), as observed in other viral disease (30-33). Another
consideration which has not yet been investigated is that the hemostatic changes seen with
COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with
severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the
setting of elevated antiphospholipid antibodies. Whether antiphospholipid antibodies play a major role in pathophysiology of thrombosis associated with COVID-19 requires further investigation (35).

**COVID-19, markers of myocardial injury, and thrombotic disease.** Elevated troponin levels are associated with poor outcomes in several studies of COVID-19 (36). However, the differential diagnosis for elevated troponin in COVID-19 is broad (37) and includes non-specific myocardial injury, impaired renal function (leading to troponin accumulation), myocarditis, pulmonary embolism (PE), and Type I and II myocardial infarction (MI) (38,39). Similarly, elevation of natriuretic peptides is non-specific (38), and consideration for thrombotic events (e.g., PE) should only be raised in the appropriate clinical context.

**COVID-19 Investigational Therapies and Considerations for Thrombotic Disease**

Several investigational agents are being tested in the management of COVID-19, especially for patients who develop severe disease. Some of these drugs have clinically important interactions with antiplatelet or anticoagulant agents (*Tables 4 and 5*).

Further, a few of these investigational agents have been associated with excess risk (or, in other cases, reduced risk) for thrombotic events, or for thrombocytopenia in prior studies of non-COVID-19 populations. For example, bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), and is under investigational use for COVID-19, is associated with increased risk for adverse cardiovascular events, including MI, cerebrovascular accidents, and VTE (40,41). Alternatively, fingolimod, an immunomodulating agent being tried for COVID-19, may reduce reperfusion injury and improve outcomes in patients suffering from acute ischemic stroke (42). Hydroxychloroquine, recently receiving Emergency Use
Authorization from the U.S. Food and Drug Administration for treatment of COVID-19, may potentially exert antithrombotic properties, especially against anti-phospholipid antibodies (43).

**COVID-19 investigational therapies and antiplatelet agents.**

Scientists are studying a number of agents for COVID-19 treatment that may have interactions with oral antiplatelet agents. Table 3 presents potential drug interactions between investigational drugs for COVID-19 and commonly administered oral antiplatelet agents.

Lopinavir/ritonavir is a protease inhibitor and inhibits CYP3A4 metabolism. Although the active metabolite for clopidogrel is mostly formed by CYP2C19, inhibition of CYP3A4 may also lead to reduction in effective dosage of clopidogrel. In contrast, inhibition of CYP3A4 may increase effects of ticagrelor. Therefore, the concomitant use of these agents along with lopinavir/ritonavir should be cautioned. Although limited clinical data exist, use of P2Y12 platelet function testing to guide the use of clopidogrel or ticagrelor in this setting might be considered. An alternative, in the absence of contraindications, is to use prasugrel, which is not prone to these interactions (44-47). Remdesivir, a nucleotide-analog inhibitor of RNA-dependent RNA polymerase, reportedly an inducer of CYP3A4; however, dose adjustments for oral antiplatelet agents are currently not recommended. Of note, there are no major drug-drug interactions between investigational COVID-19 therapies and parenteral antiplatelet agents such as cangrelor and glycoprotein IIb/IIIa inhibitors.

**COVID-19 investigational therapies and anticoagulants.**

Table 4 summarizes interactions between investigational drugs for COVID-19 and commonly administered oral anticoagulants. Lopinavir/ritonavir has the potential to also affect choice and dosage of a number of anticoagulants. For example, vitamin K antagonists, apixaban, and betrixaban may all require dose adjustment, while edoxaban and rivaroxaban should not be
co-administered with lopinavir/ritonavir. Tocilizumab, an IL-6 inhibitor, increases expression of CYP3A4; however, no anticoagulant dose adjustments are currently recommended with concomitant use of tocilizumab at this time. There are no major drug-drug interactions between investigational COVID-19 therapies and parenteral anticoagulants. Although the focus of the current manuscript is primarily related to VTE and ACS, the guidance provided for antithrombotic considerations is broadly relevant across other clinical indications.

COVID-19 and VTE

Risk stratification and in-hospital prophylaxis.

Hospitalized patients with acute medical illness, including infections such as pneumonia, are at increased risk of VTE (48,49). Prophylactic anticoagulation reduces the risk of VTE in acutely ill hospitalized medical patients (50-52), and appropriate use of VTE prophylaxis is covered in clinical practice guidelines (49,53,54). Multiple risk stratification tools are available for VTE risk assessment in this setting (e.g. the Caprini, IMPROVE, and Padua models) (55-60).

The choice of specific risk assessment model may vary across health system. However, similar to other acutely ill medical patients, VTE risk stratification for hospitalized patients with COVID-19 should be undertaken. A recent study from China, using the Padua model, reported that 40% of hospitalized patients with COVID-19 were at high risk of VTE. The study did not provide data about the use of VTE prophylaxis, or the incident VTE events (61). Hospitalized patients with COVID-19 who have respiratory failure or co-morbidities (e.g., active cancer, or heart failure) (62), patients who are bedridden, and those requiring intensive care should receive pharmacological VTE prophylaxis, unless there are contraindications. The choice of agents and dosing should be based on available guideline recommendations (53,54,63). The World Health Organization interim guidance statement recommends prophylactic daily low-molecular weight
heparins (LMWHs), or twice daily subcutaneous unfractionated heparin (UFH) (64). If pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent pneumatic compression) should be considered in immobilized patients (64,65). Missed doses of pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes (66). Therefore, every effort should be made to ensure that patients receive all scheduled doses of pharmacologic VTE prophylaxis. In this regard, once daily dosing regimen of LMWHs may be advantageous over UFH to reduce personal protective equipment (PPE) use and exposure of healthcare workers.

Consideration for risk of VTE in pregnant patients with COVID-19 deserves further attention. The risk of VTE is increased during pregnancy and the postpartum period (67,68). Although limited data are available, pregnant women admitted to hospital with COVID-19 infection are likely to be at an increased risk of VTE. It is reasonable to assess the risk of VTE and to consider pharmacological thromboprophylaxis, especially if they have other VTE risk factors. Weight-adjusted prophylactic dosing of anticoagulation is an interesting topic that requires additional investigation (69).

**Extended (post-discharge) VTE prophylaxis.**

After hospital discharge from acute medical illness, extended prophylaxis with LMWH (70) or direct oral anticoagulants (DOACs) (71-74) can reduce the risk of VTE, at the cost of increase in bleeding events, including major bleeding (75,76). While no data specific to COVID-19 exist, it is reasonable to employ individualized risk stratification for thrombotic and hemorrhagic risk, followed by consideration of extended prophylaxis (for up to 45 days) for patients with elevated risk of VTE (e.g., reduced mobility, co-morbidities such as active cancer,
and [according to some authors in the writing group], elevated D-dimer >2 times the upper normal limit) who have low risk of bleeding (74,77,78).

The role of thromboprophylaxis for quarantined patients with mild COVID-19 but significant co-morbidities, or for patients without COVID-19 who are less active because of quarantine is uncertain. These patients should be advised to stay active at home. In the absence of high-quality data, pharmacological prophylaxis should be reserved for those at highest risk patients, including those with limited mobility and history of prior VTE or active malignancy.

**Diagnosis of VTE in patients with COVID-19.**

As described above, elevated D-dimer levels, is a common finding in patients with COVID-19 (23), and does not currently warrant routine investigation for acute VTE in absence of clinical manifestations or other supporting information. However, the index of suspicion for VTE should be high in the case typical DVT symptoms, hypoxemia disproportionate to known respiratory pathologies, or acute unexplained right ventricular dysfunction.

A diagnostic challenge arises among patients with COVID-19, as imaging studies used to diagnose DVT or PE may not be pursued given risk of transmitting infection to other patients or healthcare workers and potentially due to patient instability. Moreover, imaging studies may be challenging in the setting of patients with severe ARDS who require prone positioning.

Investigation for PE is not feasible due to critical illness and prone position. Lower extremity ultrasound is also limited due to patient positioning. Deterioration of right ventricular function in this setting may be a critical finding, justifying the need for ways to diagnose and treat PE. However, it may be argued that the prognosis of patients with ARDS requiring prone position is so grave that investigation for underlying VTE may not alter the course. A potential option may
be to consider echocardiography to assess for signs of potentially worsening right ventricular dysfunction and in rare circumstances, clot in transit (79).

**Role for empiric therapeutic anticoagulation without a diagnosis of VTE.**

In view of the hemostatic derangements discussed above and observations from prior viral illnesses (80), some clinicians use intermediate-dose or full dose (therapeutic) parenteral anticoagulation (rather than prophylactic dosing) for routine care of patients with COVID-19 (81), hypothesizing that it may confer benefit to prevent microvascular thrombosis. However, the existing data are very limited, primarily based on a subgroup analysis (N=97) from a single retrospective study with limited control for potential confounders (82). A single center study from China suggested that D-dimer levels >1,500ng/mL has a sensitivity of 85.0% and specificity of 88.5% for detecting VTE events. However, the study was limited by small sample size and lack of validation. At this moment, while practitioners use a variety of prophylactic, intermediate, or therapeutic doses of anticoagulants in patients, the optimal dosing in patients with severe COVID-19 remains unknown and warrants further prospective investigation. The majority of panel members consider prophylactic anticoagulation, although a minority consider intermediate-dose or therapeutic dose to be reasonable.

**Incident venous thromboembolism.**

Few published studies have commented on incident VTE in patients with COVID-19. In a retrospective study from China, among 81 patients with severe COVID-19 admitted to ICU, 20 (25%) developed incident VTE. Of note, none of the patients had received VTE prophylaxis (85). In an preprint study of 25 patients with COVID-19 from Wuhan, who were suspected of having PE and underwent computed tomography angiography (CTA), 10 (40%) had evidence of acute PE on imaging (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771); however,
the study did not provide information related to use of VTE prophylaxis or the reason for performing CTA. In a study of 184 patients with severe COVID-19 from 3 academic medical centers in the Netherlands, the authors reported that 31% (95%CI 20-41) of patients developed incident VTE. All patients received pharmacological prophylaxis, although under-dosing was observed in 2 of the 3 participating centers (81). These findings require validation in additional studies.

It is possible but unknown that VTE remains underdiagnosed in patients with severe COVID-19. This is important, as ARDS in patients with COVID-19 is, itself, a potential etiology for hypoxic pulmonary vasoconstriction, pulmonary hypertension and right ventricular failure. Further insult from PE may be unrecoverable.

**Medical therapy for VTE.**

Therapeutic anticoagulation is the mainstay of VTE treatment (49,86,87). Selection of an agent requires consideration of comorbidities such as renal or hepatic dysfunction, thrombocytopenia and gastrointestinal tract function, and the agent will likely change across the hospital course to the time of discharge. In many ill inpatients with VTE, parenteral anticoagulation (e.g. UFH) is preferred as it may be temporarily withheld and has no known drug-drug interactions with investigational COVID-19 therapies. Concerns with UFH, however, include the time to achieve therapeutic aPTT, and increased healthcare worker exposure for frequent blood draws. Therefore, LMWHs may be preferred in patients unlikely to need procedures. The benefit of oral anticoagulation with DOACs include the lack of need for monitoring, facilitation of discharge planning, and outpatient management. The potential risk (especially in the setting or organ dysfunction) may include clinical deterioration and lack of timely availability of effective reversal agents at some centers. For patients who are ready for
discharge, DOACs or LMWH would be preferred to limit contact of patients with healthcare services required for INR monitoring for VKAs.

**COVID-19 and interventional therapies for VTE.**

Pulmonary embolism response teams (PERTs) allow for multidisciplinary care for patients intermediate and high-risk with VTE (49,88-90). During the COVID-19 pandemic, similar to other consultative services, PERTs should transition from in-person inpatient evaluation to e-consults using phone calls or telemedicine systems whenever feasible. It is important to note that, there are minimal available data demonstrating lower mortality from routine use of advanced VTE therapies (91,92). Therefore, the use of catheter-directed therapies during the current outbreak should be limited to the most critical situations. Indiscriminate use of inferior vena cava filters should be avoided (93). Recurrent PE despite optimal anticoagulation, or clinically-significant VTE in the setting of absolute contraindications to anticoagulation would be among the few scenarios in which placement of an inferior vena cava filter may be considered (11). Even after IVC filter placement, anticoagulation should be resumed as soon as feasible, and this is often done with gradually increasing doses and close observation for bleeding. With regard to reperfusion strategies for acute PE, current guideline recommendations should be followed. Intermediate-risk hemodynamically stable patients (intermediate-low risk, or intermediate-high risk PE according to ESC classification, sub-massive PE according to prior classifications) (49,87,91,94) should be managed initially with anticoagulation and close monitoring. In case of further deterioration, rescue systemic fibrinolysis should be considered, with catheter-directed options as an alternative. For patients with overt hemodynamic instability (high-risk PE according to the ESC classification, massive PE according to prior classifications) (49,87,91,94) systemic fibrinolysis is indicated, with catheter-based therapies reserved for
scenarios that are not suitable for systemic fibrinolysis. If infection control settings are equal, bedside initiation of extracorporeal membrane oxygenation (ECMO) is preferred in cases with known COVID-19 positivity or uncertain status, rather than support strategies requiring the use of a catheterization laboratory or an operating room (95). Figure 2 presents a potential algorithm for treatments based on risk due to VTE and COVID-19 severity.

The vast majority of patients with symptomatic acute deep venous thrombosis (DVT), should be managed with anticoagulation, with home treatment whenever possible. The few that may require acute endovascular techniques (either local fibrinolysis or embolectomy) include those with phlegmasia, or truly refractory symptoms (96).

COVID-19 and Acute Coronary Syndromes

COVID-19 and incident ACS.

Myocardial injury in COVID-19, as evidenced by elevated cardiac troponin levels or electrocardiographic and echocardiographic abnormalities, is associated with severe disease. Furthermore, higher troponin levels are associated with severe COVID-19 (5,97). However, not all such events are due to thrombotic ACS. While anecdotal cases of patients with COVID-19 presenting with ACS due to plaque-rupture have been described (type I MI), currently no such cases have been published. Such cases have been also previously described with influenza or other viral illnesses, and have been attributed to a combination of SIRS as well as localized vascular/plaque inflammation (10,98,99).

COVID-19 and antithrombotic therapy for ACS.

In presentations consistent with ACS due to plaque rupture (i.e. Type I MI) (39), dual antiplatelet therapy (DAPT) and full dose anticoagulation per American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC)
guidelines should be administered unless there are contraindications (100-103). In patients with perceived elevated bleeding risk, regimens with less potent antiplatelet agents, such as with clopidogrel, should be considered given that hemorrhagic complications are not uncommon. Special attention should be also given to drug-drug interactions between antiplatelet agents or anticoagulants and COVID-19 investigational therapies. Parenteral antithrombotic agents, in general, do not have known major interactions with the COVID-19 investigational therapies (Tables 4, 5).

**COVID-19 and interventional therapies for ACS.**

The American College of Cardiology (ACC) and Society for Cardiovascular Angiography and Interventions (SCAI) recently provided guidance regarding catheterization laboratory procedures in the current climate (84,104). The recommendations note that it is reasonable to continue optimal medical therapy and defer non-urgent cardiac procedures, in order to preserve PPE, hospital resources including inpatient and ICU beds, and minimize exposure for patients and healthcare workers, alike.

Prior to intervention, efforts should be made to distinguish non-specific myocardial injury, myocarditis, and true plaque rupture presentations (104). A low threshold to use transthoracic echocardiography to identify wall motion abnormalities should be considered prior to catheterization laboratory activation. Even in case of STEMI, in which primary percutaneous coronary intervention (PCI) reduces mortality and reinfarction, risk of COVID-19 transmission from patients to healthcare workers, or vice versa (asymptomatic vectors) must be considered. In light of this, individual centers in China and elsewhere have developed adjusted ACS protocols, which call for consideration of fibrinolytic therapy in selected patients with STEMI (105). Centers in which timely percutaneous coronary intervention is less feasible may be more likely
to adopt such a strategy. However, given that presentations of COVID-19 can mimic ACS (e.g. in the setting of myocarditis), fibrinolytic therapy must be used with caution.

**Critical Illness with SARS-CoV-2 and Management of Antithrombotic Agents**

The risk of VTE, which is increased in critically ill patients, is likely even higher in those with SARS-CoV-2 and critical illness. Aside from hemostatic derangements, immobility, an systemic inflammatory state, mechanical ventilation and central venous catheters contribute to VTE risk within the ICU (106-108). Nutritional deficiencies and liver dysfunction may also interfere with the production of coagulation factors (109). Alterations in pharmacokinetics in critically ill patients may necessitate anticoagulation dose adjustment (110), due to factors relating to absorption, metabolism, and renal (or hepatic) elimination of these drugs in the setting of potential organ dysfunction.

Parenteral anticoagulation is recommended in most cases in which anticoagulant therapy is needed for known thrombotic disease. UFH can be used in the setting of anticipated procedures, or in patients with deteriorating renal function. If no urgent procedures are anticipated, LMWHs are a reasonable alternative (111). In patients requiring ECMO, anticoagulation is frequently required to maintain circuit patency, especially at lower flow settings. Rates of complications are unknown in patients with SARS-CoV-2, but rates of thrombosis and hemorrhage may be as high as 53% and 16%, respectively, in other populations with respiratory failure (112). The limited outcome data that are available for ECMO in patients with SARS-CoV-2 suggest poor outcomes, with 5 of 6 patients dying in one series and 3 out of 3 in another (113,114). There are currently insufficient data to recommend anticoagulation targets for COVID-19 patients requiring ECMO (115).

**Additional considerations.**
As previously mentioned, severe COVID-19 may predispose to DIC with such patients experiencing particularly poor outcomes (7). Supportive care and addressing the underlying hypoxia or co-infection are appropriate (29). There are insufficient data to recommend transfusion thresholds that differ from those recommended for other critically ill patients. If invasive procedures are planned, prophylactic transfusion of platelets, fresh frozen plasma, fibrinogen, and prothrombin complex concentrate may be considered (29). Lastly, patients requiring targeted temperature management may exhibit prolongations of both PT and aPTT without evidence of bleeding diathesis (116). Therefore, correction of coagulopathy in unselected patients without overt bleeding, is not currently recommended.

DIC and Considerations for Antithrombotic Therapy

**Diagnosis and management.**

DIC is common in many patients with critical illness (117), including those with COVID-19 (7,118). It is uncertain whether COVID-19 has unique characteristics to cause direct activation of coagulation. The diagnosis of DIC is best established using the ISTH DIC score calculator (29). Regular laboratory monitoring of platelet count, PT, D-dimer, and fibrinogen in patients with COVID-19 is important to diagnose worsening coagulopathy. The first step in management of DIC is to identify and treat the underlying condition(s). Bacterial superinfections should be treated aggressively.

In addition to preventing VTE, LMWH prophylaxis may decrease thrombin generation and modify the course of DIC. Preliminary results, albeit with small number of events and limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118). Long-acting antiplatelet agents should be generally discontinued in most patients with DIC, unless required (e.g. recent ACS or stent implantation). For patients with moderate or severe COVID-19
and an indication for dual antiplatelet therapy (e.g. PCI within the past 3 months or recent MI) and with suspected or confirmed DIC without overt bleeding, in the absence of evidence decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet therapy if platelet count \( \geq 50,000 \), reduce to single antiplatelet therapy if \( 25,000 \leq \text{platelet count} < 50,000 \), and discontinue if platelets < 25,000. However, these guidelines may be revised upward or downward depending on the individualized relative risk of stent-related thrombotic complications vs. bleeding. Recovery from DIC is dependent on endogenous fibrinolysis breaking down the disseminated thrombi.

**Management of bleeding:**

Clinically-overt bleeding is uncommon in the setting of COVID-19. However, when bleeding occurs in COVID-19-associated DIC, blood products support should be considered as per septic coagulopathy (119). In summary, the mainstay of blood products transfusion are as follows: platelet concentrate to maintain platelet count > \( 50 \times 10^9/L \) in DIC patients with active bleeding or > \( 20 \times 10^9/L \) in those with a high risk of bleeding or requiring invasive procedures, fresh frozen plasma (FFP) (15-25 mL/kg) in patients with active bleeding with either prolonged PT and/or aPTT ratios (> 1.5 times normal) or decreased fibrinogen (< 1.5 g/L), fibrinogen concentrate or cryoprecipitate to patients with persisting severe hypofibrinogenemia (< 1.5 g/L), and prothrombin complex concentrate (PCC) if FFP transfusion is not possible. With the existing data, tranexamic acid should not be used routinely in COVID-19-associated DIC.

**Management of Patients with Thromboembolic Disease without COVID-19**

The main goal of management for patients with known or new-onset thrombotic disease but without COVID-19 is to provide sufficient antithrombotic protection, while minimizing physical contact between patients and healthcare workers and health systems. Outpatient
management or early discharge for acute VTE should be instituted when possible (120-122), and early discharge after medication stabilization for low-risk ACS or PCI for high-risk ACS should be considered (100-102). Telemedicine should be the preferred method of follow-up, and in-person visits should be reserved only for scenarios that cannot be addressed by telemedicine, or that may potentially warrant hospitalization.

In general, pharmacotherapy in patients with known thrombotic disease and without COVID-19, should be followed similar to the period prior to the pandemic. Although a recent document from the CDC indicated an increased risk of severe COVID-19 in patients receiving “blood thinners” (123), there is no evidence that antiplatelet agents or anticoagulants, increase the risk of contracting COVID-19, or of developing severe COVID-19. Sufficient education should be provided to patients for self-monitoring of symptoms, and to avoid unnecessary emergency department visits for nuisance bleeding.

For patients receiving VKAs, frequent INR monitoring may pose logistical challenges due to lockdowns and may unnecessarily increase the risk of being exposed to SARS-CoV-2. Therefore, thoughtful considerations should be given to potential alternatives, including using extended INR testing intervals if prior INRs have been stable (124). Other alternatives include home-based INR checks, if this can be set up promptly, drive-through INR testing, or switching to a DOAC or LMWHs when clinically appropriate (Figure 3). A summary of key recommendations is presented in Table 6.

Impact of COVID-19 on Healthcare Workers and Health Systems

Considerations for healthcare workers.

The CDC recommends contact and droplet personal PPE for healthcare workers in their routine care of patients with COVID-19. If an aerosol-generating procedure is being performed
(e.g. intubation, extubation, cardiopulmonary resuscitation), additional airborne PPE with an N95 respirator is recommended. Use of telemedicine in place of in-person office visits is a strategy to minimize physical exposure. Further details have been discussed elsewhere (5,104).

The following considerations specific to the care of patients with thrombotic disease may be useful. Over-the phone and telemedicine approaches should be considered for all non-urgent appointments. For necessary in-person visits, visitor restrictions and staggering of appointments are important considerations (125). For patients with COVID-19 who require urgent procedures, such as interventions for ACS, high-risk PE, or critical limb ischemia, the fewest number of staff necessary should be involved. For patients without known infection, healthcare workers should screen patients for COVID-19 exposures or infectivity, consider appropriate PPE during the procedure, and apply disinfection techniques post-procedure, as outlined previously (126). In patients who require, emergent cardiac catheterization with unknown COVID-19 status, airborne PPE with an N95 respirator and/or Powered Air Purifying Respirator is recommended (127,128).

**Considerations for health systems.**

Active involvement of health systems with respect to the care of patients with thrombotic disease are critical to achieving good outcomes for both COVID-19-infected and uninfected patients. If feasible, resources should be allocated to enable at-home or drive-through INR checks. Further, system-based considerations should be made to monitor and make necessary adjustments to algorithms for management of suspected STEMI or severe PE requiring PERT teams. If procedures are deemed necessary for COVID-19 infected patients, specific protocols should be put into place regarding PPE use and room disinfection.

**Role of Professional Societies**
Professional societies, along with other partners, have an important role in knowledge
generation and dissemination for various aspects of COVID-19 (5,84,104), as well as leading by
example. Illustrative examples include the responsible and wise decisions by the ACC to cancel
the 2020 Annual Scientific Sessions, the SCAI to cancel the 2020 Annual Scientific Sessions,
and the ISTH to cancel the XXVIII Congress of the ISTH to promote social distancing and to
avoid further spread of the disease. Enabling meetings to continue virtually, as with the recent
ACC scientific sessions (in this case at no charge) further promotes knowledge dissemination
and sense of community, allowing a semblance or normality in challenging times. Many
professional societies, including the ACC, the American Heart Association (AHA), American
Society of Hematology, ESC, the ISTH, and others, are compiling COVID-related resources in
dedicated websites. Professional societies can further foster collaborative knowledge generation
by supporting multicenter multinational original research studies to address the pressing clinical
or laboratory questions (Figure 4).

**Public Health Considerations Related to Care for Thrombotic Disease**

The WHO and government agencies have recognized the critical importance of public
health interventions at the societal level (including social distancing and self-isolation) to
decrease transmission rates and alleviate the burden on health systems (129). In the most affected
areas, governments have enacted mandatory home quarantine for all non-essential personnel
(130-132). There are several important issues to consider as these interventions relate to
thrombotic disease.

First, given the recommendations to stay at home, with decreased daily activity and
sedentary lifestyles, patients may be at increased risk for VTE (133-137). Clinicians should be
aware of this (especially in older adults and higher-risk patients) and provide education on the
importance of home activities to mitigate this risk (138). Second, as daily routines are disrupted, dietary changes (especially in daily intake of green vegetables, which are the major source of vitamin K in the Western diet) may affect patients who receive VKAs. As quarantine measures become more severe, changes in diet and vitamin K intake may impact INR values. Providers and patients should be aware of these risks, and patients should be advised to maintain stable diet to the best of their ability. Third, the COVID-19 pandemic has produced damaging economic effects (139), with United Nations estimating that COVID-19 is likely to cost the world economy more than $2 trillion in 2020. These losses may adversely affect patients’ treatment for thrombotic diseases. Socioeconomic disadvantage has been linked to higher rates of VTE and adverse outcomes (140,141). As the economic effects of COVID-19 continue to evolve, these communities may come under new and significant stress.

**Future Directions and Conclusions**

More data and higher-quality data are required to learn how COVID-19 and thrombotic disease interact. Such data, ideally derived from prospective, multicenter, multinational studies, could help to elucidate the similarities and distinctions in disease presentation and outcomes of patients with COVID-19 and preexisting and incident thromboembolic disease, and help to identify management strategies to optimize outcomes in these patients. Currently, one large international registry of patients with venous thromboembolism (the Registro Informatizado Enfermedad TromboEmbolica [RIETE]) (142) is incorporating data elements for COVID-19, and a dedicated adjudicated prospective registry to study COVID-19 and other cardiovascular outcomes is being initiated (CORONA-VTE, BWH Thrombosis Research Group; PI: G. Piazza). A multicenter multinational ACS registry is has begun and a new AHA registry for cardiovascular care and outcomes of these patients. Special attention should also be given to
patients with pre-existing thromboembolic disease who have limited access to care in the face of the COVID-19 pandemic, which has hindered transportation and limited the resources of the healthcare system.

Funding agencies, professional societies, and organizations with active patient participation will all play an important role when it comes to future research in this area. Funding agencies, including the National Institutes of Health (which has already responded swiftly) (143) should continue to pay specific attention to this pandemic. Coordination and cooperation are necessary to quickly address research priorities including those related to thrombotic disease (Table 5). Organizations such as the Patient-Centered Outcomes Research Institute (PCORI) and the North American Thrombosis Forum (NATF) can ensure the voices and concerns of patients are at the forefront of research questions. Professional societies, including the AHA, ESC, ISTH, IUA, and others should promote knowledge generation and dissemination and advocacy in this challenging climate.

The current manuscript has provided an interim summary and guidance for considerations related to thrombotic disease and antithrombotic therapy during the COVID-19 pandemic. Such guidance should supplement, rather than supplant, clinical decision-making. Nuances of conversations between patients and practitioners should be considered for appropriate patient-centered decisions.

In conclusion, thrombotic disease may be precedent factors or incident complications in patients with COVID-19. Important considerations for the preventive and therapeutic use of antithrombotic agents should be kept in mind to mitigate the thrombotic and hemorrhagic events in these high-risk patients. Funding agencies, professional societies, patients, clinicians, and
investigators should work collaboratively to effectively and efficiently address numerous critical areas of knowledge gap.
**Bullet Points**

- Coronavirus disease 2019 (COVID-19) may predispose patients to arterial and venous thrombosis.
- Initial series suggest the common occurrence of venous thromboembolic disease in patients with severe COVID-19. The optimal preventive strategy warrants further investigation.
- Drug-drug interactions between antiplatelet agents and anticoagulants with investigational COVID-19 therapies should be considered.
- The available technology should be used optimally to care for patients without COVID-19 who have thrombotic disease during the pandemic.
References


87. Jaff MR, McMurtry MS, Archer SL et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic


102. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-


126. Welt FGP SP, Aronow HD et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: A Joint statement from the American College of


Figure Legends

Figure 1. Variability in resources and testing strategies, and in contracting COVID-19 after exposure to SARS-CoV-2. Such variability explains the dissimilar population rates of the infection, and the distinct case fatality rates, across various regions and countries. Inflammatory response, increased age, and bed-ridden status – which are more frequently observed in severe COVID-19 – may contribute to thrombosis and adverse outcomes. Coronavirus Disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), VTE indicates venous thromboembolism.

Figure 2. Risk stratification of acute coronary syndromes and venous thromboembolism with COVID-19. Proposed algorithm to risk stratify patients based on severity of ACS, VTE, and COVID-19 presentations. *High-risk ACS refers to patients with hemodynamic instability, left ventricular dysfunction or focal wall motion abnormality, or worsening or refractory symptoms. High-risk VTE refers to patients with pulmonary embolism who are hemodynamically unstable, have evidence of right ventricular dysfunction or dilatation, or with worsening or refractory symptoms. †High-risk COVID-19 refers to patients with high suspicion for or confirmed COVID-19, including individuals with high viral load, symptomatic with coughing/sneezing or other respiratory symptoms and at risk for requiring intubation and aerosolizing viral particles. ‡Hemodynamic support includes intra-aortic balloon pump, percutaneous ventricular assist device, and extracorporeal membrane oxygenation. Hemodynamic monitoring refers to Swan-Ganz catheter for invasive hemodynamic assessment. For potential drug-drug interactions, please refer to Tables 4 and 5. ACS indicates acute coronary syndrome; GDMT, guideline-directed medical therapy; TTE, transthoracic echocardiogram; VTE, venous thromboembolism.
Figure 3. Considerations for Switching Vitamin-K Antagonists (VKAs) Due to Limitations with Access to Care or Healthcare Resources During COVID-19 Pandemic. If switching the anticoagulant agent is planned, care should be taken to be sure that the patient is able to afford and receive the alternative therapy. Contraindications to DOACs include mechanical heart valves, valvular AF, pregnancy or breastfeeding, APLS, and co-administration of medications including strong CYP3A and P-glycoprotein inhibitors (-azole medications, HIV protease inhibitors [dependent on DOAC, may just require dose reduction], CYP3A4 inducers (anti-epileptics), St. John’s Wort, rifampin, etc. Patient education about stable dietary habits while receiving VKA is also important. If DOACs are not available or approved by insurance, LMWHs could be used in select cases. Abbreviations: AF: atrial fibrillation, APLS: antiphospholipid syndrome, DOAC: direct oral anticoagulant, INR: international normalized ratio, LMWH: low-molecular weight heparin, VKA: vitamin-K antagonist.

Figure 4. Considerations for Thrombotic Disease for Patients, Healthcare Providers, and Health Systems and Professional Societies During the COVID-19 Pandemic. The approach to safe evaluation and management of thrombotic disease in patients with COVID-19 has several levels of involvement. Hospitalized patients with existing VTE should continue on anticoagulation with consideration of drug-drug interactions, especially with antiviral medications (Table 2). Hospitalized patients with reduced mobility should be started on VTE prophylaxis. Patients who are discharged or not hospitalized should continue recommended anticoagulation therapy. Telemedicine and drive-through or home INR checks can reduce the risk of exposure of both patients and healthcare providers to COVID-19 while assuring proper management of anticoagulation. In appropriate cases, consider switching VKAs to DOACs to diminish the need for frequent INR checks (see Figure 4). Healthcare workers should continue
existing precautions including use of PPE and minimizing individual contact with COVID-19 patients. If emergent procedures for thrombotic disease (e.g. cardiac catheterization, pulmonary thrombectomy) are needed, procedure rooms should be disinfected and the use of negative pressure operating rooms should be implemented as available. Expedited funding for observational and randomized control trials in management of thrombotic disease is encouraged.


Central Illustration. Postulated Mechanisms of Coagulopathy and Pathogenesis of Thrombosis in COVID-19. A) Sars-COV-2 infection activates an inflammatory response, leading to release of inflammatory mediators. Endothelial and hemostatic activation ensues, with decreased levels of TFPI and increased tissue factor. The inflammatory response to severe infection is marked by lymphopenia, and thrombocytopenia. Liver injury may lead to decreased coagulation and antithrombin formation. B) COVID-19 may be associated with hemostatic derangement and elevated troponin. C) Increased thromboembolic state results in venous thromboembolism, myocardial infarction, or in case of further hemostatic derangement; disseminated intravascular coagulation. COPD: chronic obstructive pulmonary disease; CRP: c-reactive protein; FDP: fibrin degradation product; HF: heart failure; TFPI: tissue factor pathway inhibitor; IL: interleukin; LDH: lactate dehydrogenase; PT: prothrombin time.
Table 1. Select Summary of Thrombotic and Thromboembolic Events During Viral Outbreaks

<table>
<thead>
<tr>
<th>Proposed Mechanisms</th>
<th>Event Type</th>
<th>Epidemiological data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe Acute Respiratory Syndrome (SARS)</td>
<td>Venous Thromboembolism</td>
<td>Retrospective analysis of 46 critically ill patients with SARS showed 11 DVT and 7 PE events.(145)</td>
</tr>
<tr>
<td>Inflammatory cytokine release</td>
<td></td>
<td>Case series of 8 SARS positive ICU patients. Autopsy identified PE in 4, and DVT in 3 individuals.(144)</td>
</tr>
<tr>
<td>Critical illness</td>
<td>Arterial Thrombotic Events</td>
<td>In a prospective series of 75 patients, 2 patients died of acute myocardial infarction (within 3-week period).(146)</td>
</tr>
<tr>
<td>Therapeutic risk factors.(144)</td>
<td></td>
<td>Case report of an NSTEMI patient who received PCI but subsequently developed STEMI several hours later, concerning for immune-mediated plaque instability.(147)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>In a case series of 206 patients with SARS, 5 developed large artery ischemic stroke with DIC present in 2/5.(148)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In a retrospective analysis of 157 patients with SARS, isolated, subclinical elevations in aPTT were noted in 96 patients and DIC developed in 4 patients.(149)</td>
</tr>
<tr>
<td>Middle East Respiratory Syndrome (MERS-CoV)</td>
<td>Other</td>
<td>In a series of 161 cases of MERS (confirmed and probable), at least 2 were reported to have a consumptive coagulopathy.(152)</td>
</tr>
<tr>
<td>Nonspecific mechanism; potentially similar to SARS. Models suggest elevated inflammatory cytokine levels.(150)</td>
<td></td>
<td>In a series of 161 cases of MERS (confirmed and probable), at least 2 were reported to have a consumptive coagulopathy.(152)</td>
</tr>
<tr>
<td>Thromogenic murine models show evidence of microvascular thrombosis.(151)</td>
<td></td>
<td>Transgenic murine models show evidence of microvascular thrombosis.(151)</td>
</tr>
<tr>
<td>Influenza</td>
<td>Venous Thromboembolism</td>
<td>Retrospective study of 119 patients showed 4 VTE events in patients receiving prophylactic anticoagulation.(154)</td>
</tr>
<tr>
<td>Possible de novo pulmonary emboli in certain cases.(153)</td>
<td></td>
<td>Case series describes 7 PE's in patients with influenza pneumonia. In 6/7 there was no evidence of DVT.(153)</td>
</tr>
<tr>
<td>Possible thrombosis due to rupture of pre-existing high risk plaques.(99)</td>
<td></td>
<td>A multicenter, observational, case-control study (n=1454) suggests lower VTE rates are associated with influenza vaccination (odds ratio: 0.74; 95% CI: 0.57-0.97).(56)</td>
</tr>
<tr>
<td>Platelet aggregation over inflamed atherosclerotic plaques noted in animal models.(155)</td>
<td></td>
<td>This is a representative but not comprehensive list of associated studies.</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Arterial Thrombotic Events</td>
<td>A self-controlled study of 364 patients hospitalized with acute myocardial infarction found an increased incidence ratio (IR=6.05, 95% confidence interval: 3.86 to 9.50) for myocardial infarction during periods after influenza compared with controls.(157) Similar evidence exists in prior studies.(158,159)</td>
</tr>
<tr>
<td>Mechanistic understanding continues to evolve. Factors may include inflammatory cytokine release and critical illness/therapeutic risk factors.</td>
<td></td>
<td>A retrospective cohort study of 119 patients reports 3 arterial thrombotic events, two of which had STEMI (154).</td>
</tr>
<tr>
<td>SARS-CoV-2 binds cells expressing angiotensin converting enzyme 2 (163) and this may mediate further mechanisms of injury.(164)</td>
<td></td>
<td>A retrospective analysis of 183 patients found non-survivors had significantly higher D-dimer and PT values, compared with survivors. Further, 15/21 (71.4%) of non-survivors met criteria for DIC, versus 1/162 (0.6%) of survivors.(7)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>This is a representative but not comprehensive list of associated studies.</td>
</tr>
<tr>
<td>DIC has been described with influenza infection in a number of case reports and small case series (160-162).</td>
<td></td>
<td>Data are continuing to emerge regarding the risk of thrombotic events associated with COVID-19 infection, and an international registry for ACS is planned. Please see text for more detail.</td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; aPTT = activated partial thromboplastin time; COVID-19 = coronavirus disease of 2019; DIC = disseminated intravascular coagulation; DVT = deep vein thrombosis; ICU= intensive care unit; MERS = Middle East Respiratory Syndrome; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; PE = pulmonary embolism; PT = prothrombin time; SARS = severe acute respiratory syndrome; STEMI = ST-elevation myocardial infarction; VTE = venous thromboembolism.
| Table 2. Association Between Coagulation Abnormalities or Markers of Thrombosis and Hemostasis and Clinical Outcomes in Patients with COVID-19 |
|---|---|---|---|---|---|---|---|---|---|---|
| | ICU vs. non-ICU | Dead vs. alive | Dead vs. alive | ICU vs. non-ICU | Dead vs. alive | Dead vs. alive | | | | |
| Platelet count | | 196 (165-263) vs. 164 (131-263) | 166 (107-229) vs. 220 (168-271) | 142 (110-202) vs. 165 (125-188) | 162 (111-231) vs. 204 (137-263) | 48 (-37 - -39)* |
| | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | | |
| | | 2.4 (0.6-14.4) vs. 0.5 (0.3-0.8) | 5.2 (1.5-21.1) vs. 0.6 (0.3-1.0) | 0.5 (0.3-0.9) vs. 0.2 (0.2-0.3) | 0.4 (0.2-1.3) vs. 0.2 (0.1-0.3) | 4.0 (1.0-11.0) vs. 0.5 (0.3-1.2) | 2.1 (0.8-5.3) vs. 0.6 (0.4-1.3) | 3.0 (2.5-3.5)* |
| | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | | |
| | | 12.7 (11.2-13.4) vs. 10.7 (9.8-12.1) | 12.1 (11.2-13.7) vs. 11.4 (10.4-12.6) | 11.3 (11.4-12.0) vs. 11.4 (10.4-12.6) | 11.3 (11.4-12.0) vs. 11.4 (10.4-12.6) | 11.6 (11.1-12.5) vs. 11.8 (11.0-12.5) | 15.5 (14.4-16.3) vs. 13.6 (13.0-14.0) | | |
| | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | Severe vs. non-severe | ICU vs. non-ICU | Dead vs. alive | | |
| | | 3.3(3.0-163.0) vs. 3.5 (0.7-5.4) | 22.2 (5.6-83.1) vs. 3.0 (1.1-5.5) | 11.0 (5.6-26.4) vs. 5.1 (2.1-9.8) | 23.6 (6.8-44.5)* | | | | | |
Table 3. Potential Drug Interactions Between Antiplatelet Agents and Investigational Therapies for COVID-19

<table>
<thead>
<tr>
<th>Investigational COVID-19 Therapies</th>
<th>Mechanism of Action of COVID-19 Therapy</th>
<th>P2Y12 Platelet Receptor Inhibitors</th>
<th>Phosphodiesterase III Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>Lopinavir is a protease inhibitor; Ritonavir inhibits CYP3A4 metabolism, increasing lopinavir levels</td>
<td>CYP 3A4 Inhibition (minor pathway): Reduction in clopidogrel active metabolite. Do not co-administer or if available utilize P2Y12 platelet function assays for monitoring † With limited clinical data, prasugrel may be considered as alternative, if no contraindications</td>
<td>CYP3A4 Inhibition: Decreased active metabolite but maintained platelet inhibition. Can administer with caution.</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Inhibits IL-6 receptor: may potentially mitigate cytokine release syndrome symptoms in severely ill patients</td>
<td>Reported increase in expression of 2C19 (major pathway) and 1A2, 2B6, and 3A4 (minor pathways): No dose adjustment recommended.</td>
<td>Reported increase in expression of CYP3A4 (major pathway): No dose adjustment recommended.</td>
</tr>
<tr>
<td>Sarilumab</td>
<td>Binds specifically to both soluble and membrane-bound IL-6Rα (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling: may potentially mitigate cytokine release syndrome symptoms in severely ill patients</td>
<td>Reported increase in expression of 3A4 (minor pathways: No dose adjustment recommended.</td>
<td>Reported increase in expression of 3A4 (major pathway): No dose adjustment recommended.</td>
</tr>
</tbody>
</table>

Other drugs being studied to treat COVID-19 include azithromycin, bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, interferon, losartan, methylprednisolone, parfendone, and ribavirin. Drug-drug interactions between these medications and antiplatelet agents have yet to be identified. *Cangrelor, aspirin, dipyridamole, and glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab) are not known to interact with investigational therapies for COVID-19. †Monitoring of P2Y12 levels can be assessed through the VerifyNow assay, or others. Evaluation of effect of protease inhibitors on P2Y12 inhibitors has not been extensively studied. Dose reduction recommendations for P2Y12 inhibitors or P2Y12 platelet function assay monitoring is not commonly practiced.
Table 4. Potential Drug Interactions Between Anticoagulants and Investigational Therapies for COVID-19

<table>
<thead>
<tr>
<th>Investigational COVID-19 Therapies</th>
<th>Oral Anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vitamin K antagonists</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Lobapavir/Ritonavir</td>
<td>CYP2C9 induction: May decrease plasma concentration. Adjust dose based on INR</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
<tr>
<td>Interferon‡</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>Mechanism not well known: Possibly decreased absorption of warfarin in the presence of ribavirin.(166) Increased dose may be needed</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
<tr>
<td>Sarilumab§</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
<tr>
<td>Hydroxychloroquine and Chloroquine</td>
<td>Unknown mechanism: Decreased dose may be needed</td>
</tr>
</tbody>
</table>

Other drugs being studied to treat COVID-19 include bevacizumab, chloroquine/hydroxychloroquine, ecuclizumab, finginglom, fousarion, and pefuridone. Drug-drug interactions between these medications and oral anticoagulants have yet to be identified. Bevacizumab has been reported to cause deep vein thrombosis (9%), arterial thrombosis (5%) and pulmonary embolism (1%). It is also reported to cause thrombocytopenia (5%) *Parenteral anticoagulants (including unfractionated or low-molecular weight heparins, bivalirudin, argatibon, and fondaparinux) are non CYP metabolized and don’t interact with any of the investigational agents *Reported with interferon alpha. (These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of these agents to be contraindicated. Interferon has been reported to cause pulmonary embolism (<5%), thrombosis (<5%), decreased platelet count (<15% with Alfa-2b formulation), and ischemic stroke (<5%). §Sarilumab has been reported to cause decreased platelet count, with decreases to less than 100,000 mm$^3$ in 1% an 0.7% of patients on 200 mg and 150 mg doses, respectively. CYP: Cytochrome P system.)
Table 5: Areas Requiring Further Investigation

<table>
<thead>
<tr>
<th>Area of Investigation</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients with Mild COVID-19 (outpatient)</strong></td>
<td>To determine the optimal method for risk assessment for outpatients with mild COVID-19 who are at risk of VTE. The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding.</td>
</tr>
<tr>
<td>To determine the incidence acute coronary syndrome in population-based studies</td>
<td></td>
</tr>
<tr>
<td><strong>Patients with Moderate or severe COVID-19 without DIC (hospitalized)</strong></td>
<td>To determine the incidence and predictors of VTE among patients with COVID-19 who present with respiratory insufficiency and/or hemodynamic instability. These include lower extremity DVTs, central-line associated DVT in upper or lower extremities, and also PE. Prospective multicenter cohort (observational) data needed; these protocols should not interfere and could run in parallel with interventional trials which are planned or already underway.</td>
</tr>
<tr>
<td>To develop an appropriate algorithm for the diagnosis of incident VTE in patients with COVID-19.</td>
<td>D-dimer is elevated in many inpatients with COVID-19, although negative value may still be helpful. In some cases of COVID-19 with worsening hypoxemia, CTPA may be considered instead of non-contrast CT (which only assesses the pulmonary parenchyma). Unresolved issues include diagnostic tests for critically-ill patients, including those in prone position, with limited options for CTPA or ultrasoundography.</td>
</tr>
<tr>
<td>To determine the optimal total duration of prophylactic anticoagulation</td>
<td>Ultrasound screening in select patients may need to be studied.</td>
</tr>
<tr>
<td><strong>Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)</strong></td>
<td>To determine if routine use of pharmacological VTE prophylaxis or low or standard dose anticoagulation with UFH or LMWH is warranted (if no overt bleeding). A relevant question is whether prophylactic, or other, dose anticoagulation should be given to patients with DIC who do not have bleeding, even without immobility.</td>
</tr>
<tr>
<td>To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis</td>
<td></td>
</tr>
<tr>
<td>To determine utility of other interventions including antithrombin concentrates</td>
<td></td>
</tr>
<tr>
<td><strong>Patients without COVID-19 but with co-morbidities, and homebound during the pandemic</strong></td>
<td>To determine if routine use of pharmacological VTE prophylaxis or low or standard dose anticoagulation with UFH or LMWH is warranted (if no overt bleeding). A relevant question is whether prophylactic, or other, dose anticoagulation should be given to patients with DIC who do not have bleeding, even without immobility.</td>
</tr>
<tr>
<td>To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis</td>
<td></td>
</tr>
<tr>
<td>To determine utility of other interventions including antithrombin concentrates</td>
<td></td>
</tr>
<tr>
<td><strong>Patients with Moderate or Severe COVID-19, and comorbidities, and homebound during the pandemic</strong></td>
<td>To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis.</td>
</tr>
<tr>
<td>To determine utility of other interventions including antithrombin concentrates</td>
<td></td>
</tr>
<tr>
<td><strong>Patients with COVID-19 but with co-morbidities, and homebound during the pandemic</strong></td>
<td>To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis.</td>
</tr>
<tr>
<td>To determine utility of other interventions including antithrombin concentrates</td>
<td></td>
</tr>
</tbody>
</table>

Table 6. Summary of Consensus Recommendation on Antithrombotic Therapy During the COVID-19 Pandemic

<table>
<thead>
<tr>
<th>Patients with Mild COVID-19 (outpatient)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For outpatients with mild COVID-19, increased mobility should be encouraged. Although indiscriminate use of pharmacological VTE prophylaxis should not be pursued, assessment for the risk of VTE and of bleeding is reasonable. Pharmacologic prophylaxis could be considered after evaluating risk VTE, without high bleeding risk.*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with Moderate or Severe COVID-19 without DIC (hospitalized)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients with moderate or severe COVID-19 who do not have recent stable INRs, and are unable to undergo home or drive-through INR testing, it is reasonable to transition the treatment DOACs if there is no high incidence of preexisting asymptomatic DVT.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with Moderate or Severe COVID-19 with suspected or confirmed DIC (hospitalized)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients who were admitted and are now being discharged for COVID-19, routine screening for VTE risk is reasonable for consideration of pharmacological prophylaxis for up to 45 days post-discharge. Pharmacological prophylaxis should be considered if there is elevated risk for thrombotic events, without high bleeding risk. *</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with COVID-19 presenting with ACS</th>
</tr>
</thead>
<tbody>
<tr>
<td>For presentations concerning for STEMI and COVID-19, clinicians should weigh the risks and severity of STEMI presentation with that of potential COVID-19 severity in the patient, as well as risk of COVID-19 to the individual clinicians and to the healthcare system at large. Decisions for primary percutaneous coronary intervention or fibrinolytic therapy should be informed by this assessment.*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with COVID-19 who have previously-known thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who were admitted and are now being discharged for COVID-19, routine screening for VTE risk is reasonable for consideration of pharmacological prophylaxis for up to 45 days post-discharge. Pharmacological prophylaxis should be considered if there is elevated risk for thrombotic events, without high bleeding risk. *</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients without COVID-19 but with co-morbid conditions (e.g. patients with new onset VTE, active cancer, major cardiopulmonary disease), who are homebound during the pandemic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations include increased mobility, and risk assessment for the risk of VTE and risk of bleeding is reasonable. Administration of pharmacologic prophylaxis could be considered after assessment on an individual case basis for patients who have elevated risk for thrombotic events, without high bleeding risk.</td>
</tr>
</tbody>
</table>

*Indicates recommendations as reached by consensus via Delphi of at least 66% of authors. When data are lacking, some panel members (55%) considered it reasonable to use intermittent pneumatic compression in patients with severe COVID-19, in addition to pharmacological prophylaxis. Specific areas of concern included limited data on use in the prone position as well as potential high incidence of preexisting asymptomatic DVT. H: VTE prophylaxis is considered, enoxaparin 40mg daily or similar LMWH regimen (e.g. dalteparin 5000U daily) can be administered. Subcutaneous heparin (5000U twice to three times per day) can be considered for patients with renal dysfunction (i.e. creatinine clearance <30 mL/min). While the majority of the writing group did make this recommendation, 31.6% of the group were in favor of intermediate-dose anticoagulation (e.g. enoxaparin 1mg/kg/day, or enoxaparin 40mg BID, or UFH with target aPTT of 50-70) and 5.2% considered therapeutic anticoagulation. The majority of the investigators recommended prophylactic anticoagulation (54%). A minority of investigators (29.7%) voted for intermediate-dose parenteral anticoagulation in this setting, and 16.2% considered therapeutic anticoagulation. While the majority of investigators voted to reduce the intensity of anticoagulation if the indication were not acute (62%), this survey question did not meet prespecified cut-off of 66%. The majority of the writing group recommended prophylaxis with DOACs (51%) and minority (24%) recommended LMWH, if available and appropriate. ACS: acute coronary syndrome; DOAC: direct oral anticoagulant, LMWH, low-molecular weight heparin; STEMI, ST-segment elevation myocardial infarction; UFH, unfractionated heparin; VTE: venous thromboembolism.
Potential for increased risk of VTE, and adverse outcomes:
- Age
- Bed-ridden, stasis
- Inflammatory response, endothelial injury
- Hemostatic abnormalities, DIC

VTE Prophylaxis, if not contraindicated
LOW-RISK COVID-19

For ACS:
- GDMT per ACS algorithm
- Urgent/emergent angiography and intervention
- Consider need and safety of hemodynamic support and monitoring

For VTE:
- Anticoagulant therapy
- If recurrent symptoms or deterioration, consider systemic thrombolysis or potentially catheter-directed therapy as an alternative
- Consider need and safety of hemodynamic support and monitoring

HIGH-RISK COVID-19 *

For ACS:
- GDMT per ACS algorithm
- Urgent/emergent angiography and intervention
- Consider need and safety of hemodynamic support and monitoring in select patients

For VTE:
- Anticoagulant therapy
- Consider systemic thrombolysis
- Catheter-directed or surgical therapies in case not suitable for systemic thrombolysis
- Consider need and safety of hemodynamic support and monitoring

LOW/INTERMEDIATE RISK ACS OR VTE

For ACS:
- GDMT per ACS algorithm
- Angiography and intervention only if recurrent/persistent symptoms or decompensation

For VTE:
- Anticoagulant therapy
- Catheter-directed or surgical therapies only if recurrent/persistent symptoms or decompensation

For ACS:
- GDMT per ACS algorithm
- Other therapies reserved for select cases such as those with significant recurrent/persistent symptoms or decompensation

For VTE:
- Anticoagulant therapy
- Other therapies reserved for select cases such as those with significant recurrent/persistent symptoms or decompensation
Were the last 2 INRs therapeutic in previous 30-60 days?
OR
Is the time-in-therapeutic range >70% in the last 2-3 months?

YES

Resume VKA. Extend testing intervals per local protocols (e.g., 2-3 months)

NO

Consider following options for INR monitoring:
- In-home INR self-testing
- Drive-through INR testing
- Schedule office or lab visit during off-peak hours

Are options above feasible?

YES

Continue Warfarin, Monitor INR

NO

Does the patient have a contraindication to use DOACs? (e.g., valvular AF, mechanical valves, AML, pregnancy/breastfeeding, cotreatments*)

YES

Continue Warfarin with INR monitoring at clinics during off-peak hours
OR
Switch to LMWH therapy if no contraindications

NO

Discontinue Warfarin and start DOAC if feasible*
PATIENTS HOSPITALIZED WITH COVID-19
- Pharmacological VTE prophylaxis, unless contraindicated
- Careful assessment for incident thrombotic events
- Follow PT/INR, APTT, D-dimer, fibrinogen
- Continuation of precedent antithrombotic therapy based on clinical condition and assessment for drug-drug interaction (see Table 2)

PATIENTS WITHOUT COVID-19 OR MILD COVID-19 / POST-DISCHARGE
- Continue therapy, unless otherwise specified by practitioners
- Extend VTE prophylaxis in appropriately selected cases
- Home INR checks or drive-through INR check for patients on VKAs who need testing
- Encourage home exercises
- Home treatment for low-risk acute VTE
- Early, safe discharge after VTE or ACS

HEALTHCARE WORKERS
- Proper use and conservation of PPE
- Outpatient tele-visits
- Minimal team structure to reduce contact with COVID-19
- Deferring elective procedures, or those of less certain benefit
- Age/comorbidity restriction for patient visits

PROFESSIONAL SOCIETIES, FUNDING AGENCIES
- Research priority setting and knowledge generation
- Advocacy and improved public knowledge
- Expedited funding for research in thrombotic disease
- Updated evidence-based guidelines

HOSPITALS AND HEALTH SYSTEMS
- Provide tele-health infrastructure
- Drive-through INR checks
- In appropriate cases, consider switching VKAs to DOACs
- Frequent disinfection of patient room
- Negative pressure procedure rooms when possible
- Cancel or postpone elective procedures and visits
- Improve knowledge generation and dissemination
**A**

**RISK FACTORS**
- Acute illness
- Bedridden, stasis
- Genetics
- Fever
- Diarrhea
- Sepsis
- Liver injury
- CKD
- COPD
- HF
- Malignancy

**INFLAMMATORY RESPONSE → ENDOTHELIAL DYSFUNCTION SUPERINFECTED**
- Tissue factor
- TFPI
- Lymphopenia
- Inflammatory cytokines
- IL-6, CRP

**B**

**HEMOSTATIC ABNORMALITIES**
- Pulmonary microthrombi
- Intravascular coagulopathy
- Myocardial injury
- ↑ Cardiac biomarkers

**C**

**CLINICAL OUTCOMES**
- Venous Thrombembolism
- Myocardial Infarction
- Disseminated Intravascular Coagulation
- ↑ D-dimer, FDPs, PT
- ↓ Platelets